Quarterly report · Q2
2784.TEDINET S100PL0M
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.33T | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥2.59T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.29T | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥10.2bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥9.1bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥11.5bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥32.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.0bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥11.1bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥10.3bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥7.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥32.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥7.0bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥7.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥7.0bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥1.33T | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥1.30T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.33T | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥852.3bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥832.2bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥481.9bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥471.8bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥492.0bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥169.5bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥180.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥168.2bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥179.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥176.0bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥169.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥10.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥36.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥20.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥15.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥2.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥6.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥29.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥34.6 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.1 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥153.57 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥33.02 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.7 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 36.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.9% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥15.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥15.2bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | ¥245m |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.18T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.17T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥8.3bn |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥8.0bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥23.6bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥17.0bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥6.6bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥842m |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥17.9bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥17.9bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥14m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥124.1bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥123.8bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥305m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥1.35T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥1.33T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥15.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥10.0bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥14.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥14.2bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | ¥182m |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥1.13T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥1.13T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥7.0bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥22.9bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥16.9bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥6.0bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥16.8bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥16.8bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | −¥285m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥129.9bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥129.6bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥284m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥1.30T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥1.29T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥14.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥8.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 539
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from sales of treasury stock fin cf | CurrentYTDDuration | 0 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -5715000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -5468000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -6947000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -6385000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 39000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 86000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 6692000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -10928000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 169060000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 179108000000 | JPY |
| Increase in cash and cash equivalents resulting from merger cce | Prior1YTDDuration | 218000000 | JPY |
| Increase in cash and cash equivalents resulting from merger cce | CurrentYTDDuration | － | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 175971000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 168180000000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 24781000000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 24420000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 5757000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 5878000000 | JPY |
| Welfare expenses sga | Prior1YTDDuration | 5128000000 | JPY |
| Welfare expenses sga | CurrentYTDDuration | 5101000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 1225000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 1124000000 | JPY |
| Packing and transportation expenses sga | Prior1YTDDuration | 12405000000 | JPY |
| Packing and transportation expenses sga | CurrentYTDDuration | 12956000000 | JPY |
| Depreciation sga | Prior1YTDDuration | 4415000000 | JPY |
| Depreciation sga | CurrentYTDDuration | 4872000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 1125417000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 129617000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02962-000ManufacturingBusinessReportableSegmentsMember | 16871000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 16799000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1288706000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 1288706000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 7932000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 284000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02962-000ManufacturingBusinessReportableSegmentsMember | 5992000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 14209000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -14209000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 1133350000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 129901000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02962-000ManufacturingBusinessReportableSegmentsMember | 22864000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 16799000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1302916000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -14209000000 | JPY |
| Net sales | Prior1YTDDuration | 1288706000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 7031000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 1093000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |